Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system by S. Rojas et al.
Journal of
Materials Chemistry B
COMMUNICATION
Pu
bl
ish
ed
 o
n 
01
 N
ov
em
be
r 2
01
3.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
10
/0
5/
20
16
 0
8:
43
:3
2.
 
View Article Online
View Journal  | View IssueDepartamento de Qu´ımica Inorga´nica, Unive
18071, Granada, Spain. E-mail: jarn@ugr.e
† Electronic supplementary information
ESI-MS, NMR, IR and diﬀuse reectanc
biological essays, N2 adsorption isot
spectroscopy data. CCDC 864943. For ES
other electronic format see DOI: 10.1039/
Cite this: J. Mater. Chem. B, 2014, 2,
2473
Received 17th October 2013
Accepted 31st October 2013
DOI: 10.1039/c3tb21455a
www.rsc.org/MaterialsB
This journal is © The Royal Society of CBiophysical characterisation, antitumor activity
and MOF encapsulation of a half-sandwich
ruthenium(II) mitoxantronato system†
S. Rojas, E. Quartapelle-Procopio, F. J. Carmona, M. A. Romero, J. A. R. Navarro*
and E. Barea*The novel non-conventional metallodrug [(h6-p-cymene)2Ru2mitox-
antronato]Cl2 (1) exhibits redox activity, DNA intercalation ability,
cathepsin B and D inhibition and in vitro antitumor activity able to
circumvent cisplatin resistance. Moreover, 1 can be successfully
incorporated intoMIL100(Fe) as a proof of concept of the feasibility of
metal–organic frameworks as carriers of non-conventional drugs.Since the clinical application of the leading cisplatin anticancer
metallodrug, a great deal of work has been devoted to nd new
compounds showing a comparable antitumor activity but with
reduced side eﬀects. In this context, some half-sandwich
organometallic Ru(II) based metallodrugs have attracted the
attention of researchers1 since some of them do not display in
vitro cytotoxicity but are active against metastasis in vivo.2 In
contrast to platinum based metallodrugs, ruthenium systems
display a generally lower cytotoxicity towards primary tumors
whichmight be related to their diﬀerent chemical properties. In
this regard, some researchers have postulated that unlike Pt(II)
metallodrugs, DNA binding is not the main mechanism of
action of Ru(II) systems but their activity might be related to the
inhibition of overexpressed enzymes in tumors (i.e. cathepsins)3
or interference with biological redox processes.4,5 On the other
hand, cancer therapies are not based on the use of a single drug
but they usually make use of a drug cocktail in order to assure
the highest eﬃciency. Thus, pure organic molecules, such as
anthracyclines of both natural and synthetic nature, are
frequently used as anticancer drugs in combination with plat-
inum drugs. The toxicity of anthracyclines is essentially due to
the noncovalent binding to DNA double helix.6 Among this
family of compounds, mitoxantrone (Scheme 1), anrsidad de Granada, Av. Fuentenueva, S/N,
s; ebaream@ugr.es; Tel: +34 958 248 093
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hemistry 2014anthraquinone derivative, is one of the most promising
compounds. It is noteworthy that this system has been proved
to exhibit a reduced cardiotoxicity compared to daunomycin
and adriamycin analogues7 while being highly active against
advanced breast cancer, non-small cell lung cancer as well as
non-Hodgkins lymphoma.8–10
On the other hand, a great eﬀort is currently being made to
develop methods that achieve the administration of bioactive
molecules, specically, for a long timeframe and at a controlled
rate. In particular, improved carriers of anticancer metallodrugs
will contribute to develop more eﬃcient treatments with less
side eﬀects. In this regard, two main benets are expected from
the use of appropriate delivering systems for these drugs: (i) the
prevention of the drug from rapid degradation in a physiolog-
ical medium and (ii) the targeted drug delivery, thanks to the
use of functionalized carriers.11
In this context, metal–organic frameworks (MOFs) – a new
class of synthetic porous crystalline materials based on metal
ions connected through spacing ligands – can be considered
good candidates for the transport and the release of these
species.12 Nowadays, MOFs have demonstrated interestingScheme 1 Reaction of [Ru(p-cymene)Cl]2Cl2 with mitoxantrone to
give [(h6-p-cymene)2Ru2mitoxantronato]Cl2 (1).
J. Mater. Chem. B, 2014, 2, 2473–2477 | 2473
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View Article Onlineapplications in diverse elds, such as separation and purica-
tion of gases,13 heterogeneous catalysis,14 nanomaterials15 and
biomedicine.12,16 Regarding the latter application, the well-
known mesoporous MOF, MIL100(Fe) ([Fe3O(H2O)2F(btc)2],
btc ¼ benzene-1,3,5-tricarboxylate), based on non-toxic iron(III)
and carboxylate ligands, has been shown to be a potential
platform for drug delivery.17 It should be highlighted that this
MOF can be obtained as nanoparticles, which is a key issue for
some administration routes in biological applications in order
to avoid tissue damage. Moreover, preliminary subacute in vivo
toxicity assays performed intravenously in rats conrm the lack
of severe toxicity of very high doses of MIL100(Fe)
nanoparticles.12
Taking into account the above information, we were inter-
ested in nding a novel metallodrug, which may combine the
action of half-sandwich Ru(II) systems with mitoxantrone in
order to give rise to dual function metal complexes with DNA
intercalating properties together with protease inhibition
features. Moreover, we were also interested in studying the
feasible encapsulation of such metallodrug into the porous
structure of MIL100(Fe) as a proof of concept of the potential
use of MOF-based methods for the delivery of non-conven-
tional anticancer metallodrugs. Indeed, our group has previ-
ously reported the incorporation/release of another
non-conventional anticancer metallodrug, [Ru(p-cymene)-
Cl2(pta)] (pta ¼ 1,3,5-triaza-7-phospaadamantane) (RAPTA-C),
into the highly porous and robust MOFs [Ni8(OH)4(OH2)2(4,40-
(buta-1,3-diyne-1,4-diyl)-bispyrazolato)6] and [Ni2(C8H2O6)]
(CPO-27-Ni).18 Then, in this communication, we present the
synthesis and biological activity of [(h6-p-cymene)2Ru2mitox-
antronato]Cl2 (1) (Scheme 1) as well as its successful incorpo-
ration into the porous matrix ofMIL100(Fe) following a ship-in-
a-bottle strategy.
[(h6-p-Cymene)2Ru2mitoxantronato]Cl2 (1) can be easily
obtained by reacting the commercial mitoxantrone$HCl drug
with one equivalent of [Ru(p-cymene)Cl]2Cl2 in ethanol at room
temperature (for experimental details see the ESI†). The
formation of the dinuclear complex in 1 is conrmed by single
crystal X-ray diﬀraction data‡ which show that mitoxantronato
coordinates two CyRu moieties acting in a N,N,O,N0,N0,O0-exo-
hexadentate bridging mode (Fig. 1). The disposition of both
CyRu moieties is above the plane of the aromatic polycyclic
system.Fig. 1 View of [(h6-p-cymene)2Ru2mitoxantronato]
2+ in the crystal
structure of 1. C (grey), N (blue), O (red), and Ru (orange). H-atoms
have been omitted for clarity.
2474 | J. Mater. Chem. B, 2014, 2, 2473–2477The 1H NMR spectrum of 1 in MeOD is indicative of the
existence of a single species in solution with a molecular
symmetry analogous to that found in the solid state (Fig. S1†).
The 1H-NMR spectrum shows the splitting of the CH2 signals of
mitoxantrone’s side chains conrming its rigid coordination
(en-like coordination mode) to the Ru atoms. The exact attri-
bution of all the proton signals has been possible with a HET-
COR spectrum. Integration of the 1H signals corresponding to
cymene and mitoxantrone moieties, also agrees with the dinu-
clear nature of 1. The MS-ESI+ spectrum further conrms the
formation of 1. Indeed the 100% peak found at the m/z value of
948.1844 corresponds to the cationic [(p-cymene)2Ru2mitoxan-
tronato]Cl+ species.
It is noteworthy that 1 is soluble in both polar solvents (H2O,
MeOH, EtOH, CH3CN, (CH3)2O, DMF) and low polar solvents
(CH2Cl2, CHCl3) which might be attributed to the presence of
both polar (O, OH, NH) as well as apolar residues (Cy) in this
system. These characteristics are of interest since they may
favor the solubility of 1 in body uids as well as its internali-
zation inside tumor cells.
In view of all these features we have studied the possible
interaction of 1 with relevant biomolecules, its redox activity as
well as its cytotoxicity.
Taking into account the DNA-intercalating features of
mitoxantrone, we have studied the possible eﬀect of the pres-
ence of the (Cy)Ru sides in 1 on its interaction with the DNA
structure, by means of diﬀerent biophysical methods: circular
dichroism (CD) and competitive binding with ethidium
bromide (EB). The experiments have been performed on both 1
and free mitoxantrone in order to have a reliable comparison
between results. It is noteworthy that the results prove that the
bulk of the (Cy)Ru residues coordinated to mitoxantrone does
not signicantly hamper the DNA intercalating ability of the
mitoxantrone residue. Indeed, the EB competitive assays reveal
that DNA binding constant values show only a slight decrease
from 2.85  107 M1 for mitoxantrone to 2.18  106 M1 for 1
(Fig. 2). The intercalative binding mode is further conrmed by
CD measurements showing the diminution of DNA ellipticity
for both mitoxantrone and 1 (Fig. S6†).
We have also studied the possible interaction of 1 with
additional biological targets, namely, amino acids and prote-
ases. The results (Fig. S7†) show that this system readily reacts
with both S-donor (cysteine, glutathione) and N-donor (histi-
dine) amino acids as previously found in related half-sandwich
Ru(II) systems which involve coordination to the biorelevant
ligands as well as redox processes.19 Indeed, 1H NMR studies of
the incubation of 1 (MeOD, 37 C; DMSO-d6, 37 C) with pure
amino acids (Fig. S7†) show a rather fast (<4 h) interaction
between complex 1 and the corresponding amino acid with the
concomitant liberation of free mitoxantrone.
Moreover, 1 is also able to interact with proteases, inhibiting
their enzymatic activity. Indeed, the uorescence binding assay
of 1 with cathepsin D proved that a 20 mM solution of 1 can
completely inhibit the activity of this protease (Fig. S8†).
Furthermore, 1 can also inhibit cathepsin B activity exhibiting
an IC50 value of 1.5 mM (Fig. S9†) which is below the one
reported for RAPTA-C (IC50 ¼ 2.5 mM)20 and other Ru-basedThis journal is © The Royal Society of Chemistry 2014
Fig. 2 Competitive binding assays: ﬂuorescence spectra of interca-
lated ethidium bromide (5 mM) in DNA (4 mM) upon addition of
increasing amounts of mitoxantrone (above) and 1 (below) in 1 mM
sodium cacodylate buﬀer and 20 mM NaCl. Inset: relative drug
concentration vs. ﬂuorescence intensity.
Table 2 IC50
a values (in mM) in ovarian (A2780) and cisplatin resistant
(A2780cis), breast cancer (MCF-7) and lymphoma (HL-60) cancer cell
lines and healthy kidney cells (LLC-PK1). Resistance factor RF (IC50
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View Article Onlinemetallodrugs.4 It is noteworthy that mitoxantrone (200 mM)
does not aﬀect the substrate hydrolysis rate for both cathepsin B
and D which points that protease inhibition activity should be
related to Ru binding ability to amino acids (see above). These
results are of interest in view of the exacerbated metabolism of
these types of enzymes in cancer cells.3
As above mentioned, the possible biological activity of Ru
metallodrugs can also be related to their involvement in bio-
logical redox processes.4 In this regard, we have studied the
redox activity of 1 as well as mitoxantrone and that of [Ru(p-Cy)-
Cl]2Cl2 precursors, by means of cyclic voltammetry (Table 1).
The results for complex 1 show a shi of mitoxantrone’s
oxidation waves to higher potentials (DE ¼ +0.12 V), indicative
of increasing diﬃculty for mitoxantrone oxidation upon Ru
binding, as a consequence of charge withdrawal from metal
centres. The rst anodic wave corresponds to the partiallyTable 1 Summary of redox properties for mitoxantrone, [Ru(p-cym-
ene)Cl]2Cl2 and 1
Compound Epa (V) Attribution Epc (V) Attribution
Mitoxantrone 0.44 2e, 1,4-OH — —
1.17 2e, aminoalkyl 0.972 1e, anthracene
[RuCyCl)2]Cl2 1.34 2e
 Ru(II/III) 1.12 2e, Ru(II/I)
1 0.56 1e, 1-OH 0.90 1e, anthracene
0.89 1e, 4-OH 1.50 2e, Ru(II/I)
This journal is © The Royal Society of Chemistry 2014reversible (Fig. S4†) transfer of 1e (comparison with Fc/Fc+ 1e
oxidation process) to the OH group in position 1 of the
anthracene moiety. The second peak (irreversible) is attributed
to the oxidation of the second OH group of mitoxantronato
(Fig. S3†). Regarding the reduction process of 1, an irreversible
reduction peak is observed in the rst place (Fig. S5†) which can
be attributed to the reduction of the mitoxantronato in 1. The
second peak is again irreversible and is attributed to the
simultaneous reduction of the two Ru atoms in the transition
Ru II/I. The latter process is more diﬃcult (i.e. occurs at more
negative potentials) than in the case of the [(RuCyCl)2]Cl2
complex and this can be easily understood if we consider that
the system has already accommodated one electron on the
mitoxantronato ligand and consequently the next reduction
step is less favourable. As a concluding remark it should be
noted that the biologically relevant redox behaviour of 1 is
basically ligand centred since the most accessible processes
take place at the mitoxantronato moiety.
Finally, we have studied the in vitro antitumor activity of 1
towards selected cancer cell lines, namely wild type (A2780) and
cisplatin resistant ovarian tumor (A2780cis), breast cancer
(MCF-7), and lymphoma (HL-60) cell lines as well as its cyto-
toxicity towards healthy kidney cells (LLC-PK1). The results are
summarised in Table 2 showing a remarkably high antitumor
activity for system 1 towards both wild type and cisplatin
resistant tumor cell lines. It is noteworthy that the IC50 values
for 1 and resistance factors are below the ones obtained for the
drug cisplatin for three out of the four assayed cell lines, thereby
suggesting a high eﬀectiveness of 1 towards these types of
tumor cells. Nevertheless, the cytotoxic activity for 1 is slightly
below the one exhibited by free mitoxantrone for all the tested
cell lines, although it shows a lower resistance factor. It is
noteworthy that 1 exhibits a lower cytotoxicity towards healthy
kidney cells compared to free mitoxantrone which should be
taken as an advantageous feature. It might be concluded that
the observed diﬀerences in biological activity of 1 compared to
free mitoxantrone should be related to the diminution of the
intercalating activity of 1 as a consequence of the bulk of the
CyRu residues and/or the slow release of the free mitoxantrone
drug upon complex degradation in the biological media. It
should also be noted that cathepsins inhibition activity of 1,cisplatin resistant/IC50 cisplatin sensitive)
Mitoxantrone 1 Cisplatin (control)
MCF-7 0.011(1) mM 28(4)b % 15(1) mM
A2780 0.043(1) mM 0.58(1) mM 0.91(5) mM
A2780cis 0.032(2) mM 0.25(1) mM 7.37(53) mM
RF 0.74 0.43 8.10
HL-60 0.16(1) mM 1.94(2) mM 8.18(19) mM
LLC-PK1 21(5)b % 15(4)b % 12(1) mM
a IC50: drug concentration necessary for 50% inhibition of cell viability.
b Growth inhibition at 100 mM drug concentration.
J. Mater. Chem. B, 2014, 2, 2473–2477 | 2475
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View Article Onlinechanges the redox activity of mitoxantrone, and slow release of
free mitoxantrone may eventually give rise to a diﬀerent (dual)
mechanism of action and/or selectivity in vivo.
Taking into account the interesting antitumor activity of 1,
we decided to study its incorporation into the mesoporous
metal–organic framework system MIL100(Fe). Nanoparticles of
MIL100(Fe) were prepared as described in the literature (for
experimental details see ESI†).21 Thermal activation of
MIL100(Fe) at 383 K removes the coordinated water guest
molecules leaving large cavities of 2.9 nm of diameter ready for
adsorption of other molecules. As a rst attempt we tried to load
1 into the porous matrix by suspending it in saturated solutions
of 1 in diﬀerent solvents (i.e. acetone, ethanol). However, the
loading of the metallodrug was not achieved by impregnation
probably due to the small size of the pore windows (0.86 nm 
0.86 nm). In order to circumvent this problem, we successfully
carried out the incorporation of 1 into MIL100(Fe) following a
ship-in-a-bottle strategy (Scheme 2) as a means of achieving the
direct synthesis of 1 inside the pores of MIL100(Fe). For this
purpose, a three step reaction was performed (Scheme 2): (i)
rst, MIL100(Fe) was ground in an acetone solution of
[Ru(H2O)3Cl3], which led to its rapid encapsulation; (ii) then,
loaded [Ru(H2O)3Cl3] was reacted with a-terpinene in EtOH
under reux for 24 h to form the dinuclear complex [Ru(p-cym-
ene)Cl]2Cl2 and (iii) in the third step, the latter dinuclear complex
was reacted withmitoxantrone in EtOH at 313 K for 24 h to give 1
(Scheme 2). The formation of 1was conrmed by: (i) the dramatic
reduction of the adsorption capacity of the MOF (SBET drops
from 1570 m2 g1 for the original material to 20 m2 g1 aer 1
loading) (Fig. S12†); (ii) the presence of the main peaks of pure 1
in the IR spectrum ofMIL100(Fe)@1 (Fig. S10†); (iii) the presence
of characteristic bands of 1 in the reectance diﬀuse spectrum of
MIL100(Fe)@1 (Fig. S11†) and (iv) the content of Ru in
MIL100(Fe)@1 conrmed by energy dispersive X-ray spectros-
copy (Fig. S13†).
Some preliminary attempts to deliver the 1 system from
MIL100(Fe) in SBF show a rather complex behaviour, in which
the degradation of 1 (see above) and MOF nanoparticles17Scheme 2 Strategy for the encapsulation of 1 into the porous matrix
of MIL100(Fe).
2476 | J. Mater. Chem. B, 2014, 2, 2473–2477overlap. These facts hamper a clear understanding of the
delivery process. Nevertheless, it should be noted that a possible
benet of the encapsulation strategy proposed herein,
compared to the encapsulation of free mitoxantrone alone,
might be related to the slow and simultaneous release of both
species, namely Ru(II) organometallic fragments and mitoxan-
trone. Ongoing research in our group is being focused on
clarifying the potential biological activity of nano-
MOF@metallodrug hybrid systems.
Conclusions
In summary, a new mitoxantronato half-sandwich Ru(II) system
has been prepared and fully characterized. It is noteworthy that
this system can be considered as a multitarget antitumor met-
allodrug exhibiting redox activity, DNA intercalation, protease
inhibition as well as important in vitro antitumor activity.
Moreover, we have demonstrated that it is possible to load this
metallodrug into the porous matrix of MIL100(Fe) following a
ship-in-a-bottle procedure. The latter result should be taken as a
proof of concept of the potential use of metal–organic frame-
works as carriers of non-conventional anticancer drugs. The
development of delivering strategies may help to circumvent
some problems of anticancer therapies related to the stability of
the drug in the physiological medium (higher reactivity of Ru(II)
vs. Pt(II)) as well as its selective delivery to the cancer cells, which
will decrease the undesirable side eﬀects of the treatments.
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